News

Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association

June 11, 2024

Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance

Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI

Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates

April 4, 2024

Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change

February 28, 2024

Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change

February 28, 2024

Trinity Biotech to Present at Emerging Growth Conference

February 8, 2024

Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code

February 8, 2024

Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc.

January 31, 2024

Trinity Biotech Announces Q3 2023 Financial Results Business Update

January 31, 2024

Trinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya

December 28, 2023

Trinity Biotech Announces Management Changes

December 27, 2023

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

Trinity Biotech Announces Q2 2023 Financial Results

Trinity Biotech plc to Announce Q2 Fiscal Year 2023 Financial Results

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement

Trinity Biotech Announces That It Has Received 510(k) Clearance From The U.S. Food and Drug Administration for the Premier Resolution System

Trinity Biotech Announces Q1 2023 Financial Results

Trinity Biotech plc to Announce Q1 2023 Financial Results

July 4, 2023